908 Devices Inc (MASS)vsNovartis AG ADR (NVS)
MASS
908 Devices Inc
$9.52
+1.82%
HEALTHCARE · Cap: $414.99M
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 93084% more annual revenue ($56.69B vs $60.84M). NVS leads profitability with a 22.5% profit margin vs -57.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
MASS
Avoid31
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+47.5%
Fair Value
$12.58
Current Price
$9.52
$3.06 discount
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Revenue surging 23.3% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -27.2% — below average capital efficiency
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : MASS
The strongest argument for MASS centers on Debt/Equity, Price/Book, Revenue Growth. Revenue growth of 23.3% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : MASS
The primary concerns for MASS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
MASS profiles as a growth stock while NVS is a value play — different risk/reward profiles.
MASS carries more volatility with a beta of 0.63 — expect wider price swings.
MASS is growing revenue faster at 23.3% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 31/100), backed by strong 22.5% margins. MASS offers better value entry with a 47.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
908 Devices Inc
HEALTHCARE · MEDICAL DEVICES · USA
908 Devices Inc. develops and sells measuring devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and Asia Pacific. The company is headquartered in Boston, Massachusetts.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?